Mark HU Senior Counsel +86 10 64096099
Return Team download

Practice experience

Mark has over 17 years of extensive experience in multinational companies and a reputable PRC law firm. Before joining Lifang & Partners, he served as Legal Counsel at Novartis, Senior Legal Counsel at Medtronic, Senior Legal Counsel at Reckitt and Compliance Director at Pfizer.
His practice focuses on corporate compliance, intellectual property and general corporate.
In the field of corporate compliance, Mark assists domestic and foreign enterprises in addressing compliance and regulatory issues related to anti-bribery, data privacy and cybersecurity, anti-unfair competition, and import and export controls, especially in the field of healthcare, where he has a very strong expertise. During his tenure at Pfizer, Novartis, and Reckitt, he was responsible for compliance risk control across multiple business and functional departments, helping the companies establish, operate, and improve compliance risk management systems, and properly handle crisis events, government investigations, and internal investigation cases. During his tenure at Novartis, he served as the data privacy officer and led the development and implementation of China data compliance system, and also provided advice to internal clients on issues such as data privacy protection, cross-border transmission, and risk event response.
In the field of intellectual property, Mark provides legal services to enterprises in areas such as intellectual property layout and strategic consulting, intellectual property due diligence, technology licensing (License in/out) and technology transfer, technology achievement transformation, FTO, patent invalidation and infringement litigation, trademark and brand protection, copyright and trade secret protection. He was responsible for supporting the intellectual property affairs of Medtronic China R&D Center, assisting in patent prosecution and layout, establishing and improving intellectual property management systems, handling patent licensing, collaborative research and development, etc. He also served as an intellectual property consultant for Medtronic China Venture Capital Fund, responsible for due diligence, FTO analysis, and other work on fund investment projects. During his time at FMCG giant Reckitt, he supported trademark and brand protection for several well-known pharmaceutical, hygiene and health brands. He also served as the Vice Chairman of the Member Service Committee of the Quality Brand Protection Committee (QBPC) of the China Association of Foreign Investment Enterprises, providing support for the brand and innovation protection of well-known Chinese and foreign enterprises.
In the field of general corporate, Mark handles legal issues for various enterprises, including investment and financing, M&A, corporate governance, contract review, employment, product quality, dispute resolution, bankruptcy liquidation, etc. He has served large foreign-invested, state-owned and private enterprises such as Novartis, Reckitt, Medtronic, China Mobile, UPC Renewables, Genting Power, and GLU Mobile in this field. He is proficient in company law and commercial law, and is skilled in combining his work experience within enterprises and law firms to gain insight into the business needs of clients and provide pragmatic solutions.

Main Works and Speeches

-“Analysis of Key Legal Issues for License in/out of Drug and Device Technology (Part 1): A Comprehensive Overview and Main Process Sorting”, November 9, 2023, Lifang Observation
-“Series Articles on Anti-corruption Compliance in Healthcare Industry (Part 1): How Healthcare Companies Effectively Control Compliance Risks of HCP Speaker Fees”, September 18, 2023, Lifang Observation
-“The Latest Changes in the Regulation of Human Genetic Resources in China and Its Impact on Healthcare Industry”, June 10, 2023, Lifang Observation
- Speech: “Academic Promotion and Compliance Practice of Pharmaceutical Enterprises under the Anti-bribery Storm”, October 29, 2023, Sai Bai Lan Pharmaceutical Compliance Seminar
- Speech: “Regulatory Compliance Risks and Solutions in Cross-border Pharmaceutical Licensing Transactions”, October 18, 2023, 8th Intellectual Property Frontier Pharmaceutical Forum
- Speech: “Regulatory Issues in Cross-border Licensing Transactions of Medical Devices”, October 10, 2023, Cardiovascular Medical Device Intellectual Property Forum
- Speech: “How Healthcare Companies Effectively Control Compliance Risks of HCP Speaker Fees”, September 13, 2023, E-Drug Healthcare Executives
- Speech: “Analysis of Key Points for Medical Device Licensing Transactions”, July 11, 2023, China Medical Device Intellectual Property Development Summit Forum
- Speech: “Legal and Compliance Issues of Pharmaceutical Enterprises under PAP and Innovative Payment Models”, May 17, 2023, EverPro Compliance Forum
- LLM, Temple University
- Master of Laws, East China University of Political Science and Law
- Bachelor of Medicine, Tongji University

- Chinese Lawyer Qualification
- Chinese Patent Attorney Qualification

Working Languages
- Chinese
- English

Business field

  • Intellectual Property Law
  • Antitrust and Unfair Competition
  • Corporate and Commercial Law

Copyright © 2020      Lifang Partners    京ICP备09037220号-1      京公网安备11010102000452号